ORGANOIDSCIENCES (476040) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of ORGANOIDSCIENCES stock KRW 3,951, price KRW 4,710, that is 16.1% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
ORGANOIDSCIENCES
476040 · KQExpensive (fair value 16% below the price), weak company and falling price: meets none of the 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 16, 2026.
How to read this chart
18‑month range 4,710 KRW – 48,150 KRW · fair‑value band 2,963 KRW – 4,938 KRW · the 4,710 KRW price screens above the 3,951 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 16, 2026.
Every Wednesday you see whether ORGANOIDSCIENCES is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Organoidsciences Ltd. develops regenerative therapies in South Korea.
Show moreShow less
It develops ATORM, an adult tissue derived organoid based regenerative medicine platform for the treatment of intractable intestinal ulcers, as well as salivary glands, liver, and uterus disease areas; ODISEI solutions, an organoid-based discovery platform for screening evaluation and identification; and EXPANSION, an organoid-based advanced science for innovative solutions.
The company was founded in 2018 and is based in Seongnam-si, South Korea.
Stock analysis
ORGANOIDSCIENCES (476040) currently trades at 4,710 KRW, while our estimate is 3,951 KRW, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: 2,963 KRW (bear) to 4,938 KRW (bull), the price of 4,710 KRW sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
ORGANOIDSCIENCES reported revenue of 2.4B KRW in FY2025 versus 270M KRW in FY2021, a compound +72.7%/yr. Reported net income was −15.4B KRW in FY2025.
Key figures
Market cap 31.0B KRW (≈ $23.1M) Micro · P/S ratio 15.7 · EPS (TTM) −2,802 KRW · Return on equity −62.3% · Return on assets (EBIT) −32.0% (5-year average) · Operating margin −728% · Revenue (TTM) 2.3B KRW · Revenue growth (YoY) −1.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 89% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, 476040 screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Revenue & earnings trend
Compare ORGANOIDSCIENCES with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 848 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Return on assets by industry
- Fair value gap by industry
- Piotroski F-Score screener with fair value
- Undervalued stocks: South Korean Stocks
- Valuation of the Korea market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs 476040 |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs 476040 |
| Samsung Biologics Co 207940 | 1,423,000 KRW | 1,552,100 KRW | +9% | vs 476040 |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs 476040 |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs 476040 |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs 476040 |
| BeOne Medicines AG 6160 | HK$249.40 | HK$152.92 | −39% | vs 476040 |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs 476040 |
| Celltrion, Inc 068270 | 214,500 KRW | 74,945 KRW | −65% | vs 476040 |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs 476040 |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is ORGANOIDSCIENCES (476040) overvalued or undervalued?
What is the fair value of 476040?
What is the quality score of 476040?
What is the price target for ORGANOIDSCIENCES (476040)?
What is the ORGANOIDSCIENCES stock forecast for 2026?
What is the revenue of ORGANOIDSCIENCES (476040)?
What is the intrinsic value of ORGANOIDSCIENCES (476040)?
Is ORGANOIDSCIENCES stock overvalued or undervalued in 2026?
Is fair value the same as the market price of 476040?
How much is ORGANOIDSCIENCES worth?
What do the bullish and bearish scenarios say about 476040?
How solid is the balance sheet of ORGANOIDSCIENCES (476040)?
How far is 476040 from its 52-week high?
Which stocks are comparable to ORGANOIDSCIENCES?
Is ORGANOIDSCIENCES stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of ORGANOIDSCIENCES (476040)?
What should I pay attention to with ORGANOIDSCIENCES right now?
Key figures of ORGANOIDSCIENCES
How large is the market capitalisation of ORGANOIDSCIENCES (476040)?
What is the P/S ratio of ORGANOIDSCIENCES (476040)?
What are the earnings per share of ORGANOIDSCIENCES (476040)?
What is the return on equity of ORGANOIDSCIENCES (476040)?
What is the EBIT return on assets of ORGANOIDSCIENCES (476040)?
What is the operating margin of ORGANOIDSCIENCES (476040)?
How fast is revenue growing at ORGANOIDSCIENCES (476040)?
How much free cash flow does ORGANOIDSCIENCES (476040) generate?
How much net debt does ORGANOIDSCIENCES (476040) carry?
Watch ORGANOIDSCIENCES in the live analysis
One click puts ORGANOIDSCIENCES on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.